Werewolf Therapeutics appoints Anil Singhal to Board; Derek DiRocco to resign at 2025 annual meeting

Werewolf Therapeutics, Inc.

Derek DiRocco, M.D. resigns from Board, effective at 2025 annual meeting; no disagreement cited.
Anil Singhal, Ph.D. appointed as Class I director, effective Feb 19, 2025; joins Audit Committee.
Dr. Singhal has >30 years biopharma R&D experience; currently President & CEO of Trishula Therapeutics.
Dr. Singhal receives annual cash comp of $40,000 + $7,500 for Audit Committee; option for 45,000 shares at $1.40, vesting over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Derek DiRocco, M.D.

Director

HOWL · Werewolf Therapeutics, Inc.

Filed: February 24, 2025, 6:59 PM ET

On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.

Appointed

Anil Singhal, Ph.D.

Director

HOWL · Werewolf Therapeutics, Inc.

Effective: 2025-02-19
Filed: February 24, 2025, 6:59 PM ET

On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Derek DiRocco, M.D. resigned as Director at Werewolf Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anil Singhal, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.

View on SEC.gov

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-032804

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.